ZhiHong Liu1, ZhiHong Wang1, YingMing Xiao2, You Lu3, YiPing Lu4. 1. Department of Urology, West China Hospital, Sichuan University, Chengdu 610041, China. 2. Department of Urology, The Second People's Hospital of Sichuan, Chengdu 610041, China. 3. Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu 610041, China. 4. Department of Urology, West China Hospital, Sichuan University, Chengdu 610041, China. Electronic address: ypinglu@hotmail.com.
Abstract
INTRODUCTION: Interleukin-6 (IL-6), a central proinflammatory cytokine, may be involved in the host response to cancer. We therefore aimed to evaluate the association of the IL-6 gene polymorphisms at positions -174 and -572 with predisposition to renal cancer. MATERIALS AND METHODS: We conducted a hospital-based case-control study. A total of 432 subjects, including 216 pathologically-proven renal cancer cases and 216 age- and gender-matched healthy controls, were recruited in this study. Polymorphism for the IL-6 gene was genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). RESULTS: Patients with renal cancer had a significantly higher frequency of IL-6 -174 CC genotype [odds ratio (OR)=2.08, 95% confidence interval (CI)=1.05, 4.13; P=0.04] than healthy controls. When stratifying by the grade, patients with higher grade (grade 3 or 4) renal cancer had a significantly higher frequency of IL-6 -174 CC genotype (OR=2.33, 95% CI=1.04, 5.23; P=0.04). CONCLUSION: This study is, to our knowledge, the first to examine prospectively an increased risk role of IL-6 -174 CC genotype in renal cancer susceptibility.
INTRODUCTION:Interleukin-6 (IL-6), a central proinflammatory cytokine, may be involved in the host response to cancer. We therefore aimed to evaluate the association of the IL-6 gene polymorphisms at positions -174 and -572 with predisposition to renal cancer. MATERIALS AND METHODS: We conducted a hospital-based case-control study. A total of 432 subjects, including 216 pathologically-proven renal cancer cases and 216 age- and gender-matched healthy controls, were recruited in this study. Polymorphism for the IL-6 gene was genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). RESULTS:Patients with renal cancer had a significantly higher frequency of IL-6 -174 CC genotype [odds ratio (OR)=2.08, 95% confidence interval (CI)=1.05, 4.13; P=0.04] than healthy controls. When stratifying by the grade, patients with higher grade (grade 3 or 4) renal cancer had a significantly higher frequency of IL-6 -174 CC genotype (OR=2.33, 95% CI=1.04, 5.23; P=0.04). CONCLUSION: This study is, to our knowledge, the first to examine prospectively an increased risk role of IL-6 -174 CC genotype in renal cancer susceptibility.